-i\ \t

i
J
I
,r

HPV XpressMatrixrM makes use of PCR amplif ication and Hybridization

Technology to genotype the samples with specific HPV DNA probes,
which capture 95% of HPV subtypes in cervical specimens.

Based on the principle of hybrization of double-stranded DNA

complementary, the hybrization technology works by directing the {low
of the targeting molecules towards the specific HPV DNA probe immobilized
on membrane hence enables raoid hvbridization to occur and obtain
the specif ic hVbridization results. S 'rnrl,ff"ro A,ra.oeo Karya Anak Bsngs6
*i i#[|l?- Brdens Fsrmisrdan Arat Kesehstan 2016
k {DnNFsr^ bi \,i _rsr.l, ol loa rl^ o/ l'loorcs a

=s--
r-qFa.

I Solution A PCR Mix I Hybridization Solutiox

I Solution B Hotstar Taq Polymerase (not include) I Post Hybridization Solution
t Solution C HPV Type 16 DNA I Blocking Solution
(Positive Control)
I Enzyme Coniugate
DNase Free Water I Wash Solution I
(No Template Control)
t Wash Solution ll
I NBT/ BCIP
T HPV XPressMatrix" Membrane

I
i
rlu /r
} a- @
.A
-r-$i,,'' .i{'
Conlact lJs
PT. Kalcen DNA
Kornp ek Bintang Toedjoe, Jl Jend. Ahnrad Yan No 2 Pllomas, Jaka a Timur 13210 - ndonesia
Iep. +6221 - 47862449, 4702939 Ema I : kdna@kalbe.ca.id
KatrynODNA
'P'

<>.\x
i
{! '.: i.

.,8
&r
15.
^st
^X'
HPV XpressMotrix" Ki t
"PCR based method for cervical cancer screening" tr@
Background
Human paplllomavlrus (HPV) infection is sexually transmitted, now 99.7% well-established cause of ceruical cancer(').
Cervical cancer is the second most prevalence cancer lor female , wlth 2O.92/o incidence rate and 10.3% mortality rate
in lndonesla('l

Our paper (Murdiyarso et al 201 6) has validated the use of HPV XpressMatrixrM Kit to screen tor HPV inlection and cervical
cancer risk assessment, has helped us identity women older than 30 years old that should undergo both HPV and liquid pap
smear co-testing. Moreover, we have showed that HPV genotypes 52, 16, 18, and 45 are most prevalent subtypes and
relevant to cervical carcinogenesis in Indonesia. {1) Dara Acc€ssed, 2oi7 (z) wHo, zo14

Competitive Advantage:
1. Detect 21 HPV gsnotypes:
15 High risk subtypes: HPV 16, 18, 31 , 33, 35, 39, 45, 51 , 52, 53, 56, 58, 59, 66, 68
6 Low risk subtypes: HPV 6, 11, 42,43,44,81
2, Using low throughpul technology
3. Passing WHO HPV LABNET proficiency lest
4. Cost elf icient operation for low sample volume
5. Atfordable multiplex genotyping
6. Registored in Ministry of Health ot Indonesia
7. Kit is reliable as it has been used for the sarvice

. HPV XorossMatrlx
DNA Extractlon Klt , 4

Subiype 16 Nogalive Subtype No T€mplale Control

(Singl€ lnlectJon) 11, 42, 43,81
r HPV XprassMatrlxiM Klt
PCR Ampllficatlon Genotype Mapping :

. HPV XpfessMatrlx* Klt 3l Low Rlsk

Hybrldlzation Kll HPV genotyping mapping
31
can be immediately
36 39 51
HPV
interpreted by visually
52 53 53 Hlgh Rlsk observing the membranes.
03 €3